Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT AGITATION trial II – children ≤1 year
2024-520075-28-01Phase 2Authorised
- Sponsor
- Rigshospitalet
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2 trial of clonidine in Emergence agitation (EA) (2 arms), sponsored by Rigshospitalet. Primary endpoints: Emergence agitation incidence and Pharmacokinetic parameters. Planned start Jan 2025; status: authorised.
02
Drugs
clonidine
03
Conditions
Emergence agitation (EA)
Beyond the preview
Go deeper on 2024-520075-28-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520075-28-01.